JAMA

Online Prescribing of Diabetes and Weight Loss Medications

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

This secret shopper study examines the prescription process for obtaining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) from online sellers.

  • The study reveals variability in the clinical engagement required to obtain GLP-1 RAs online.
  • Different online sellers demonstrate differing levels of adherence to prescription protocols.
  • The findings suggest potential gaps in the oversight of online pharmaceutical practices.
  • Variations in the prescription processes may influence patient access to GLP-1 RAs.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

2 of 4
authors report competing interests
PubMed
FDA grants to two authors and a JAMA deputy-editor role.

Related papers

Apr '25
Safety of compounded GLP-1 receptor drugs based on FDA adverse event reports
top 30% journal
cited by 19 papers
journal article
Nov '24
Differences by Social and Demographic Factors in Off-Label Use of Diabetes Drugs in Sweden
top 10% journal
cited by 9 papers
journal article
Dec '20
Use of Glucagon-Like Peptide-1 Receptor Agonists in Japanese People with Type 2 Diabetes: A Retrospective Database Study
top 20% journal
cited by 17 papers
journal article
May '25
Challenges Croatian GPs face in prescribing diabetes medicines that also help the heart
top 20% journal
cited by 8 papers
journal article
Apr '25
Patient, Caregiver, and Clinician Experiences and Opinions of GLP-1 Receptor Agonist Treatments
top 10% journal
cited by 8 papers
journal article
Jan '22
Effectiveness and safety of high-dose hormone treatments targeting blood sugar control in type 2 diabetes
cited by 26 papers
journal article
Aug '25
Changes in prescribing patterns of drugs that activate the glucagon-like peptide 1 receptor
top 30% journal
cited by 26 papers
observational study
Jul '19
Glucagon-like peptide-1’s role in reproduction and its potential for treatment
top 1% journal
cited by 88 papers
journal article

Featured in

GLP-1 TherapiesGLP-1 TherapiesIssue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
↗

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
1 week ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
2 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
3 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
4 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
5 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
6 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
7 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
8 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
9 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
10 weeks ago8 studies
explore the archive
See more issues from the glp-1 therapies brief